Paradigm Biopharmaceuticals (ASX:PAR) will proceed with a phase 3 knee osteoarthritis trial of Zilosul, following a 30-day review by the US Food and Drug Administration of its clinical trial protocol, according to a Thursday filing with the Australian bourse.
The study's primary endpoint is a change from baseline in pain using injectable pentosan polysulfate sodium, with changes in the Patient's Global Impression of Pain, functional assessments at specific time points, and structural changes as secondary endpoints, the filing said.
Patient enrollment will start in the first quarter of next year at 10 Australian clinical trial sites, followed by US sites, as per the filing.
The company's shares tumbled almost 14% in recent Thursday trade.
Price (AUD): $0.50, Change: $-0.08, Percent Change: -13.91%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。